Insulin (Oral Inhalation)

• It is used to lower blood sugar in patients with high blood sugar (diabetes).

• Follow how to store closely. Read the package insert that comes with this medicine. If you have questions about how to store insulin, talk with your pharmacist.
• Be sure you know how long you can store this medicine before you need to throw it away.
• Throw away the inhaler 15 days after first use and get a new one.
• Keep all drugs in a safe place. Keep all drugs out of the reach of children and pets.
• Check with your pharmacist about how to throw out unused drugs.

(IN soo lin)

• Insulin, Rapid-Acting

Hypersensitivity to regular insulin or any component of the formulation; during episodes of hypoglycemia; chronic lung disease such as asthma or COPD, due to risk of bronchospasm.

Documentation of allergenic cross-reactivity for insulin is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.

There are no specific dosage adjustments provided in the manufacturer's labeling (has not been studied). Use with caution; increased glucose monitoring and dose reductions may be necessary.

Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy.

Prior to use (sealed package): Store at 2ºC to 8ºC (36°F to 46°F). If foil package is not refrigerated, contents must be used within 10 days.

In use: Once foil package has been opened, store blister cards and strips at room temperature 25ºC ( 77ºF); excursions are permitted between 15°C and 30°C (59°F and 86°F). Unopened blister cards and strips must be used within 10 days; opened strips must be used within 3 days. Inhaler may be stored refrigerated, but should be at room temperature prior to use. Cartridges should also be at room temperature for 10 minutes before administration.

Plasma glucose, electrolytes, HbA1c (at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; quarterly in patients not meeting treatment goals or with therapy change [ADA 2017a]); renal function; hepatic function, weight; PFTs at baseline, after the first 6 months of therapy and yearly thereafter. Frequently monitor patients with wheezing, persistent or recurring cough, bronchospasm, or breathing difficulties. In patients at risk for DKA (eg, acute illness or infection), increase glucose monitoring frequency.